You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 270 No. 3, July 21, 1993 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Special Communication
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Evolving Toward Effective Therapy for Acute Ischemic Stroke

Marc Fisher, MD; Julien Bogousslavsky, MD

JAMA. 1993;270(3):360-364.


Abstract

Acute ischemic stroke is a common, devastating disorder without beneficial therapy. Recent advances concerning the pathophysiology of ischemic brain injury have led to the development of rational pharmacological interventions. Thrombolytic and cytoprotective therapies may be useful and are being evaluated in clinical trials. The design of adequate clinical trials to evaluate these promising therapies has also evolved based on experience. Potential therapy for acute ischemic stroke must be assessed in a large number of patients who are given the intervention within hours of onset using a neurological scoring scale and a disability scale. Several new magnetic resonance imaging technologies are emerging that should allow the clinician to rapidly and accurately identify ischemic brain lesions and to evaluate cerebral perfusion. The availability of potentially efficacious therapies for ischemic stroke evaluated in well-designed clinical trials with magnetic resonance imaging technology, which can also assess therapeutic effects in vivo, should lead to the emergence of therapy to improve the outcome of patients with ischemic stroke in the near future.

(JAMA. 1993;270:360-364)



Author Affiliations

From the Department of Neurology, The Medical Center of Central Massachusetts and The University of Massachusetts Medical School, Worcester (Dr Fisher); and the Department of Neurology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (Dr Bogousslavsky).


Footnotes

Reprint requests to The Medical Center of Central Massachusetts, 119 Belmont St, Worcester, MA 01605 (Dr Fisher).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Recent progress in drug treatment for acute stroke
DEVUYST and BOGOUSSLAVSKY
J. Neurol. Neurosurg. Psychiatry 1999;67:420-425.
FULL TEXT  

Effects of Citicoline Combined With Thrombolytic Therapy in a Rat Embolic Stroke Model • Editorial Comment
Andersen et al.
Stroke 1999;30:1464-1471.
ABSTRACT | FULL TEXT  

Ethical Challenges in Stroke Research
Slyter
Stroke 1998;29:1725-1729.
ABSTRACT | FULL TEXT  

Further Evolution Toward Effective Therapy for Acute Ischemic Stroke
Fisher and Bogousslavsky
JAMA 1998;279:1298-1303.
ABSTRACT | FULL TEXT  

Thrombolysis in acute stroke
Bogousslavsky
BMJ 1996;313:640-641.
FULL TEXT  

Considerations in the Design of Clinical Trials of Neuroprotective Therapy in Acute Stroke
Dorman and Sandercock
Stroke 1996;27:1507-1515.
FULL TEXT  

Undergraduate and Postgraduate Medical Education for Cerebrovascular Disease
Alberts
Stroke 1995;26:1849-1851.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.